UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

(2009) Michael S. Braun et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

(2009) Erika Cecchin et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

(2009) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

(2008) E. Aranda et al.   ANNALS OF ONCOLOGY

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

(2008) Eva Martinez-Balibrea et al.   EUROPEAN JOURNAL OF CANCER

Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials

(2008) B. H. O'Neil et al.   ONCOLOGIST

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer

(2008) Georg Lurje et al.   Pharmacogenetics and Genomics